The Coronavirus Update

As Omicron fades, specialists seek answers for patients who can’t shake symptoms.

“Monoclonal antibodies should first go to patients at the highest risk of death from COVID-19, but the opposite happened …, ” says a Harvard Chan School researcher.

The “milder” outcomes of Omicron are likely due to more population immunity rather than the virus’ properties, according to new research.

Mistrust of vaccine is high among people of color in U.S. and U.K., but unequal access appears to be greater barrier in U.S., researchers say.

For babies born during this pandemic, a study published in JAMA Pediatrics suggests their brains may not fully develop.

With Omicron on the decline in some states, pandemic experts permit themselves hope, at least for the near term.

Sex differences in COVID death rates vary by state and across time, suggesting social factors play a role.

Researchers detect the COVID-19 variant in the blood and placentas of women who had stillbirths and pregnancy complications.

Leading experts offer insights as case numbers surge to record highs nationwide and new in-person semester nears.

Traditional dosing regimens of COVID-19 vaccines available in the United States do not produce antibodies capable of recognizing and neutralizing the Omicron variant, reports a new study.

Harm to kids and families outweighs COVID risks, says Harvard Chan School expert Joe Allen.

Experts say fast-spreading, less severe profile of Omicron is emerging as cases drop in South Africa but warn of challenging weeks ahead.

Harvard Med specialist says cases of remdesivir-resistant disease seem rare, may not become big issue.

At Harvard, Anthony Fauci outlined early Omicron findings and urged more robust efforts to bring the pandemic under control, including global vaccination.

Early findings on immune escape and transmissibility, combined with danger posed by Delta, heighten urgency of vaccination, testing, other safety measures.

As governments and health officials navigate pandemic, researchers stress the danger that comes with bad information.

An observational study finds that antibody levels are higher when health care workers received the SARS-CoV-2 vaccine in the afternoon.

A new study led by Harvard researchers models future SARS-CoV-2 mutations and forecasts their ability to evade immune defenses developed by vaccines and antibody-based treatments.

With Omicron landing in the U.S. this week, Harvard epidemiologist William Hanage reviewed what we know and the many things still unknown about the fast-moving coronavirus variant.

Breakthrough COVID-19 cases in vaccinated people may be less likely to spread infection because virus is shed for a shorter period of time as opposed to infections in unvaccinated people.

In a comparison study, the Moderna vaccine was slightly more effective than the Pfizer vaccine in preventing COVID-19 infection, hospitalization, and death.

Harvard professors and advisory group members detail where things stand and where they might go.

Mary Bushman, a research fellow in the Department of Epidemiology at Harvard Chan School, co-authored a recent paper that modeled variant threats.

A Harvard expert shares insight on the science and history of vaccine boosters and why we need them, speculating on a future that includes periodic COVID boosters.

Long COVID’s laundry list of ills include skepticism and doubt often conveyed in the doctors’ office.

New research points to a well-known and widely available drug called disulfiram (marketed as Antabuse) as a possible treatment for COVID-19.

Harvard specialists say COVID-19 pills may cut hospitalizations and deaths and offer big boost to nations struggling with low vaccination rates.

A human Intestine Chip has helped identify drugs that can target GI symptoms associated with both the common cold and SARS-CoV-2 virus infections.

A new decision-support tool helped preserve the health care workforce by distinguishing symptoms associated with COVID-19 vaccinations from symptoms of the virus itself.

Pediatric infectious disease specialist Kristin Moffitt offers parents insight on recently approved COVID-19 vaccines for children ages 5 to 11.